Completed PHASE3 INTERVENTIONAL 2-arm NCT05701124

Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity

Intravitreal Ranibizumab Injection In Aggressive Retinopathy Of Prematurity Compared With Type 1 Prethreshold Retinopathy Of Prematurity

Sponsor: Cairo University

Conditions Ranibizumab Retina Disease Retinopathy of Prematurity

Interventions Ranibizumab (0.25 mg/0.025 mL)

Updated 3 times since 2023 Last updated: Jan 26, 2023 Started: Nov 20, 2020 Primary completion: Nov 20, 2022 Completion: Nov 20, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05701124, this PHASE3 trial focuses on Ranibizumab and Retina Disease and remains completed. Sponsored by Cairo University, it has been updated 3 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2023 — Jul 2024 [monthly]

Completed PHASE3

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cairo University
Zagazig University

Data source: Zagazig University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zagazig, Egypt